Citius Oncology
CTOR
13 hedge funds and large institutions have $43.8M invested in Citius Oncology in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
4.25% less ownership
Funds ownership: 47.44% → 43.19% (-4.3%)
13% less funds holding
Funds holding: 15 → 13 (-2)
50% less capital inflows, than outflows
Capital inflows: $4.13M | Capital outflows: $8.29M
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Logan Stone Capital
Chicago,
Illinois
|
+$2.73M |
| 2 |
Cowen and Company
New York
|
+$1.26M |
| 3 |
Mizuho Securities USA
New York
|
+$140K |
| 4 |
Quarry LP
New York
|
+$2.24K |
| 5 |
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$2.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Capital Management
Chicago,
Illinois
|
-$4.13M |
| 2 |
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.21M |
| 3 |
Spartan Fund Management
Toronto, Ontario,
Canada
|
-$1.83M |
| 4 |
Wolverine Asset Management
Chicago,
Illinois
|
-$58.5K |
| 5 |
Glazer Capital LLC
New York
|
-$51.2K |
CTOR Hedge Fund Activity: Q2 2024 in Review
13 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q2 2024, worth a combined $43.8M — down 6.6% from $46.9M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CTOR and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Logan Stone Capital, opening a new position worth an estimated $2.73M. The largest seller was First Trust Capital Management, exiting entirely with an estimated $4.13M sold.
- 13 institutional investors held Citius Oncology (CTOR) as of Q2 2024, down from 15 in Q1 2024.
- Funds reported $43.8M of Citius Oncology stock for Q2 2024, down 6.6% quarter-over-quarter.
- 1 fund opened new Citius Oncology positions in Q2 2024 and 3 closed out, a net change of -2 holders.
- The largest Citius Oncology buyer in Q2 2024 was Logan Stone Capital, an estimated $2.73M added.
- The largest Citius Oncology seller in Q2 2024 was First Trust Capital Management, an estimated $4.13M sold.
Based on aggregated 13F filings for Q2 2024.